Race Oncology Limited

Informe acción ASX:RAC

Capitalización de mercado: AU$243.8m

Race Oncology Dirección

Dirección controles de criterios 1/4

El CEO de Race Oncology es Daniel Tillett , nombrado en Nov 2023, tiene una permanencia de menos de un año. compensación anual total es A$1.12M, compuesta por 13% salario y 87% primas, incluidas acciones y opciones de la empresa. posee directamente un 10.13% de las acciones de la empresa, por valor de A$24.69M. La antigüedad media del equipo directivo y de la junta directiva es de 0.9 años y 2 años, respectivamente.

Información clave

Daniel Tillett

Chief Executive Officer (CEO)

AU$1.1m

Compensación total

Porcentaje del salario del CEO13.0%
Permanencia del CEOless than a year
Participación del CEO10.1%
Permanencia media de la direcciónless than a year
Promedio de permanencia en la Junta Directiva2yrs

Actualizaciones recientes de la dirección

Recent updates

Is Race Oncology (ASX:RAC) In A Good Position To Deliver On Growth Plans?

Aug 26
Is Race Oncology (ASX:RAC) In A Good Position To Deliver On Growth Plans?

We Think Race Oncology (ASX:RAC) Needs To Drive Business Growth Carefully

May 10
We Think Race Oncology (ASX:RAC) Needs To Drive Business Growth Carefully

We're Not Very Worried About Race Oncology's (ASX:RAC) Cash Burn Rate

Jan 23
We're Not Very Worried About Race Oncology's (ASX:RAC) Cash Burn Rate

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Oct 05
Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Companies Like Race Oncology (ASX:RAC) Are In A Position To Invest In Growth

Jun 20
Companies Like Race Oncology (ASX:RAC) Are In A Position To Invest In Growth

We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow

Feb 17
We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow

Here's Why We're Not At All Concerned With Race Oncology's (ASX:RAC) Cash Burn Situation

Oct 14
Here's Why We're Not At All Concerned With Race Oncology's (ASX:RAC) Cash Burn Situation

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Apr 01
Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

We're Hopeful That Race Oncology (ASX:RAC) Will Use Its Cash Wisely

Apr 05
We're Hopeful That Race Oncology (ASX:RAC) Will Use Its Cash Wisely

What Percentage Of Race Oncology Limited (ASX:RAC) Shares Do Insiders Own?

Mar 01
What Percentage Of Race Oncology Limited (ASX:RAC) Shares Do Insiders Own?

How Much Are Race Oncology Limited (ASX:RAC) Insiders Taking Off The Table?

Jan 07
How Much Are Race Oncology Limited (ASX:RAC) Insiders Taking Off The Table?

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Daniel Tillett en comparación con los beneficios de Race Oncology?
FechaCompensación totalSalarioIngresos de la empresa
Jun 30 2024AU$1mAU$145k

-AU$14m

Mar 31 2024n/an/a

-AU$12m

Dec 31 2023n/an/a

-AU$11m

Sep 30 2023n/an/a

-AU$11m

Jun 30 2023AU$836kAU$332k

-AU$10m

Mar 31 2023n/an/a

-AU$10m

Dec 31 2022n/an/a

-AU$11m

Sep 30 2022n/an/a

-AU$11m

Jun 30 2022AU$1mAU$228k

-AU$11m

Mar 31 2022n/an/a

-AU$10m

Dec 31 2021n/an/a

-AU$9m

Sep 30 2021n/an/a

-AU$8m

Jun 30 2021AU$1mAU$167k

-AU$6m

Mar 31 2021n/an/a

-AU$5m

Dec 31 2020n/an/a

-AU$4m

Sep 30 2020n/an/a

-AU$4m

Jun 30 2020AU$147kn/a

-AU$4m

Compensación vs. Mercado: La compensación total ($USD728.87K) de Daniel está en línea con el promedio de empresas de tamaño similar en el mercado Australian ($USD688.70K).

Compensación vs. Ingresos: La compensación de Daniel ha aumentado mientras la empresa no es rentable.


CEO

Daniel Tillett

less than a year

Permanencia

AU$1,118,157

Compensación

Dr. Daniel Tillett is Non-Executive Director of Tryptamine Therapeutics Limited from November 8, 2024. Dr. Tillett joined the Tryptamine Therapeutics Limited on November 8, 2024. Dr. Tillett has been Chief...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Peter Smith
Executive Chairman1.4yrsAU$327.72ksin datos
Daniel Tillett
CEO, Managing Director & Directorless than a yearAU$1.12m10.13%
A$ 24.7m
Michelle Rashford
Chief Medical Officer1.3yrsAU$704.81ksin datos
Brendan Brown
Chief Financial Officerless than a yearsin datossin datos
Sophia Moscovis
Vice President of Operations & Strategyless than a yearsin datossin datos
Peter Webse
Company Secretary8.5yrssin datossin datos

0.9yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de RAC no se considera experimentado ( 0.9 años antigüedad media), lo que sugiere un nuevo equipo.


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Peter Smith
Executive Chairman1.4yrsAU$327.72ksin datos
Daniel Tillett
CEO, Managing Director & Directorless than a yearAU$1.12m10.13%
A$ 24.7m
Martin Tallman
Member of Scientific Advisory Board7.9yrssin datossin datos
Douglas Smith
Member of Scientific Advisory Boardno datasin datossin datos
Roland Walter
Member of Scientific Advisory Boardno datasin datossin datos
Borje Andersson
Chairman of Clinical Advisory Board4.9yrsAU$815.36ksin datos
Jaap-Jan Boelens
Member of Clinical Advisory Board4.8yrssin datossin datos
Jianjun Chen
Member of Scientific Advisory Board3.6yrssin datossin datos
James Breitenbucher
Member of Scientific Advisory Board2.5yrssin datossin datos
Daniel Hoff
Clinical Advisory Boardless than a yearsin datossin datos
Erin Howden
Member of Scientific Advisory Boardless than a yearsin datossin datos
Serge Scrofani
Independent Non-Executive Directorless than a yearsin datossin datos

2.0yrs

Permanencia media

Junta con experiencia: La junta directiva de RAC no se considera experimentada (2 años de permanencia promedio), lo que sugiere una nueva junta directiva.